

19 Jul 2020 |

Quick Listen: Scrip's Five Must-Know Things

Coronavirus, Other Infectious Diseases In Focus

by **Ian Haydock**

Join us for a quick audio roundup of five useful things to know from *Scrip's* recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around *Scrip's* Five Must-Know Things, in this episode covering the business week ended 17 July.

This week, there are calls for a renewed focus on and investment in infectious diseases in general, as coronavirus vaccine and drug developments continue to attract substantial attention.

Stories mentioned in this episode:

(Also see "[Moderna's COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses](#)" - Scrip, 14 Jul, 2020.)

(Also see "[Gilead's Comparative Analysis To Bolster Remdesivir Draws Criticism](#)" - Scrip, 10 Jul, 2020.)

(Also see "[Novartis Unveils Zero Profit COVID-19 Drugs Portfolio](#)" - Scrip, 16 Jul, 2020.)

(Also see "[Big Pharma's \\$1Bn Antibiotic Development Fund Offers 'Breathing Room' For Reimbursement Fix](#)" - Scrip, 9 Jul, 2020.)

(Also see "[Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base](#)" - Scrip, 15 Jul, 2020.)

[Click here to explore this interactive content online](#) ✎

